| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Canarypox virus ALVAC strain containing the FeLV-env, FeLV-gag and FeLV-pol genes from the feline leukemia virus
Record information and status
Record ID
45049
Status
Published
Date of creation
2008-05-01 11:29 UTC (manoela.miranda@cbd.int)
Date of last update
2012-09-06 16:04 UTC (dina.abdelhakim@cbd.int)
Date of publication
2012-09-06 16:04 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Canarypox virus ALVAC strain containing the FeLV-env, FeLV-gag and FeLV-pol genes from the feline leukemia virus
Transformation event
ALVAC-FL
Developer(s)
Merial Japan Limited
2-14-2 Nagata-cho
Chiyoda-ku, Tokyo
Japan, 100-0014
Phone:+81-3-5251-8182
Fax:+81-3-5251-8195
Url:http://jp.merial.com/index.asp
Description
The recombinant canarypox-feline leukemia virus is known as ALVAC-FL, or vCP97. The attenuated live ALVAC-FL is used as a vaccine against feline leukemia.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Canarypox virus - CNPV
Point of collection or acquisition of the recipient organism
Strain: Canarypox virus ALVAC strain
Characteristics of the transformation process
Vector
vCP97
Techniques used for the modification
  • Homologous recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
Feline leukemia virus envelope glycoprotein - Feline leukemia virus - Feline leukemia virus
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Feline leukemia virus gag gene - Feline leukemia virus - Feline leukemia virus
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Feline Leukemia Virus pol gene - Feline leukemia virus - Feline leukemia virus
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
The genetic sequence of the glycoprotein (FeLV-env gene), a portion of the reverse transcriptase (FeLV-pol gene) and the complete nucleoprotein (FeLV-gag gene) from the feline leukemia virus were inserted into the genomic DNA of a plaque purified isolate of the parent canarypox strain ALVAC.

The transfer of the target genes into ALVAC is done by co-transfecting chicken embryonic fibroblast cells with (i) the expression cassette plasmid into which the target genes (FeLV-env, -gag and -pol) and the promoter had been transferred by the calcium phosphate method and (ii) the rescue canarypox virus (ALVAC strain), causing homologous recombination in the cytoplasm and thus transferring the target gene into ALVAC.

Note: The disease "feline leukemia" is cased by a virus (the "feline leukemia virus", FeLV). FeLV is usually transmitted between infected cats when the transfer of saliva or nasal secretions is involved. If not defeated by the animal's immune system, the virus can be lethal. Despite the its name, the disease is not a form of cancer. The name stems from the fact that the first disease associated with the virus was a form of leukemia, and by the time it was discovered that the virus was the causal agent, the misleading name was already being used by pet owners.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Additional Information
Other relevant website address or attached documents

Records referencing this document (2)
IDDescription
2record(s) found
Country's Decision or any other Communication1 record
Risk Assessment1 record